Prognostic Value of Controlled Attenuation Parameter by Transient Elastography

American Journal of Gastroenterology

Volumn 112, Issue 12, 2017, Pages 1812-1823

  Liu, Ken ^a,b   Wai Sun Wong, Vincent ^a   Lau, Keith ^a   Du Liu, Sienna ^a   Tse, Yee Kit ^a   Cheuk Fung Yip, Terry ^a   Kwok, Raymond ^a   Yiu Wa Chan, Alex ^a   Lik Yuen Chan, Henry ^a   Lai Hung Wong, Grace ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; GLUCOSE;

ACUTE CORONARY SYNDROME; ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED ATTENUATION PARAMETER; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENTING; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DIGESTIVE TRACT PARAMETERS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PLATELET COUNT; PRIORITY JOURNAL; PROGNOSIS; TRANSIENT ELASTOGRAPHY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMPLICATION; DIAGNOSTIC IMAGING; ELASTOGRAPHY; FATTY LIVER; LIVER TUMOR; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

CARDIOVASCULAR DISEASES; COHORT STUDIES; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 85039865416     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2017.389     Document Type: Article

References (48)

1. Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep 2013;1:19–26.
2. Friedrich-Rust M, Ong MF, Martens S et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960–74.
3. European Association for Study of Liver. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237–64.
4. Sasso M, Beaugrand M, de Ledinghen V et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36:1825–35.
5. Karlas T, Petroff D, Sasso M et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66:1022–30.
6. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636–42.
7. Soresi M, Tripi S, Franco V et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 2006;26:1119–25.
8. Cheng JY, Wong VW, Tse YK et al. Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. Hepatology 2016;64:1507–17.
9. Wong GL, Chan HL, Yu Z et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 2014;39:883–93.
10. Permutt Z, Le TA, Peterson MR et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease—MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012;36:22–9.
11. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–21.
12. Kim D, Kim WR, Kim HJ et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357–65.
13. Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865–73.
14. Armstrong MJ, Adams LA, Canbay A et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014;59:1174–97.
15. Younossi ZM, Stepanova M, Rafiq N et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011;53:1874–82.
16. Ekstedt M, Hagström H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of followup. Hepatology 2015;61:1547–54.
17. Mellinger JL, Pencina KM, Massaro JM et al. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study. J Hepatol. 2015;63:470–6.
18. Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454–62.
19. Boursier J, Zarski JP, de Ledinghen V et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013;57:1182–91.
20. de Lédinghen V, Hiriart JB, Vergniol J et al. Controlled attenuation parameter (CAP) with the XL probe of the Fibroscan®: a comparative study with the M probe and liver biopsy. Dig Dis Sci. 2017; doi: 10.1007/s10620-017-4638-3 [e-pub ahead of print].
21. Chan HL, Wong GL, Choi PC et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009;16:36–44.
22. Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343–50.
23. de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.
24. Kwok R, Choi KC, Wong GL et al. Screening diabetic patients for nonalcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2016;65:1359–68.
25. Wong VW, Petta S, Hiriart JB et al. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. J Hepatol. 2017;67:577–84.
26. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012;10:646–50.
27. Söderberg C, Stål P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595–602.
28. Rafiq N, Bai C, Fang Y et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234–8.
29. Dam-Larsen S, Franzmann M, Andersen IB et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750–5.
30. Wong VW, Wong GL, Tsang SW et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011;60:829–36.
31. Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.
32. Ascha MS, Hanouneh IA, Lopez R et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972–8.
33. Sanyal AJ, Banas C, Sargeant C et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006;43:682–9.
34. Robic MA, Procopet B, Métivier S et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011;55:1017–24.
35. Vergniol J, Foucher J, Terrebonne E et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011;140:1970–9.
36. Kim SU, Lee JH, Kim DY et al. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS ONE 2012;7:e36676.
37. Masuzaki R, Tateishi R, Yoshida H et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009;49:1954–61.
38. Wong VW, Wong GL, Yip GW et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011;60:1721–7.
39. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382:339–52.
40. Vasan RS, Sullivan LM, Wilson PW et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005;142:393–402.
41. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010;9:154–69.
42. Lauby-Secretan B, Scoccianti C, Loomis D et al. Body fatness and cancer--viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794–8.
43. Tilg H, Diehl AM. NAFLD and extrahepatic cancers: have a look at the colon. Gut 2011;60:745–6.
44. Lee YI, Lim YS, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol 2012;27:91–5.
45. Hwang ST, Cho YK, Park JH et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol 2010;25:562–7.
46. White MC, Holman DM, Boehm JE et al. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46:S7–S15.
47. Roulot D, Costes JL, Buyck JF et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011;60:977–84.
48. Wong VW, Chu WC, Wong GL et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409–15.